Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-dose, randomized, open-label, three-way crossover comparative bioavailability study of RIZAPORT® 10 mg, Maxalt®-MLT 10 mg orally disintegrating tablets and Maxalt®-Lingua 10 mg oro-dispersible tablets

Trial Profile

A single-dose, randomized, open-label, three-way crossover comparative bioavailability study of RIZAPORT® 10 mg, Maxalt®-MLT 10 mg orally disintegrating tablets and Maxalt®-Lingua 10 mg oro-dispersible tablets

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rizatriptan (Primary) ; Rizatriptan
  • Indications Migraine
  • Focus Pharmacokinetics; Registrational
  • Sponsors IntelGenx Corp.
  • Most Recent Events

    • 22 Oct 2019 According to an IntelGenx Corp media release, the New Drug Application(NDA) for RIZAPORT VersaFilm for the treatment of acute migraines has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date for completion of the review of March 26, 2020.
    • 26 Sep 2019 According to an IntelGenx Corp media release, the company announced that it has resubmitted its 505(b)(2) New Drug Application(NDA) for RIZAPORT VersaFilm for the treatment of acute migraines to the U.S. Food and Drug Administration (FDA). This resubmitted NDA is subject to the FDA's acceptance review, the results of which are expected within 30 days.
    • 02 Apr 2019 According to an IntelGenx Corp media release, the company has received a Complete Response Letter (CRL) from the U.S. FDA regarding its resubmitted 505(b)(2) New Drug Application (NDA) for RIZAPORT VersaFilm for the treatment of acute migraines. The issues cited in the CRL relate to the Chemistry, Manufacturing and Controls section of the application. The Agency requested additional information, but no new bioequivalence study. RIZAPORT NDA resubmission anticipated the before the end of Q3-2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top